Archival Report| Volume 76, ISSUE 1, P40-46, July 01, 2014

Download started.


The Effects of Subanesthetic Ketamine Infusions on Motivation to Quit and Cue-Induced Craving in Cocaine-Dependent Research Volunteers

Published:September 16, 2013DOI:


      Cocaine dependence involves problematic neuroadaptations that might be responsive to modulation of glutamatergic circuits. This investigation examined the effects of subanesthetic ketamine infusions on motivation for quitting cocaine and on cue-induced craving in cocaine-dependent participants, 24 hours postinfusion.


      Eight volunteers with active DSM-IV cocaine dependence not seeking treatment or abstinence were entered into this crossover, double-blind trial. Three 52-min intravenous infusions were administered: ketamine (.41 mg/kg or .71 mg/kg) or lorazepam 2 mg, counterbalanced into three orderings in which ketamine .41 mg/kg always preceded the .71 mg/kg dose. Infusions were separated by 48 hours, and assessments occurred at baseline and at 24 hours postinfusion. Outcomes were change between postinfusion and preinfusion values for: 1) motivation to quit cocaine scores with the University of Rhode Island Change Assessment; and 2) sums of visual analogue scale craving ratings administered during cue exposure.


      Compared with the active control lorazepam, a single ketamine infusion (.41 mg/kg) led to a mean 3.9-point gain in University of Rhode Island Change Assessment (p = .012), which corresponds to an approximately 60% increase over preceding values. There was a reduction of comparable magnitude in cue-induced craving (p = .012). A subsequent ketamine infusion (.71 mg/kg) led to further reductions in cue-induced craving compared with the control. Infusions were well-tolerated.


      Subanesthetic ketamine demonstrated promising effects on motivation to quit cocaine and on cue-induced craving, 24 hours postinfusion. Research is needed to expand on these preliminary results and to evaluate the efficacy of this intervention in clinical settings.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. UNODC (2012): United Nations Office on Drugs and Crime. World Drug Report 2012. New York: United Nations

        • Karila L.
        • Gorelick D.
        • Weinstein A.
        • Noble F.
        • Benyamina A.
        • Coscas S.
        • et al.
        New Treatments for cocaine dependence: A focused review.
        Int J Neuropsychopharmacol. 2008; 11: 425-438
        • Schmidt H.D.
        • Pierce R.C.
        Cocaine-induced neuroadaptations in glutamate transmission: Potential therapeutic targets for craving and addiction.
        Ann N Y Acad Sci. 2010; 1187: 35-75
        • Kalivas P.W.
        The glutamate homeostasis hypothesis of addiction.
        Nat Neurosci. 2009; 10: 561-572
        • Ulys J.D.
        • LaLumiere R.T.
        Glutamate: The new frontier in pharmacotherapy for cocaine addiction.
        CNS Neurol Disord Drug Targets. 2008; 7: 482-491
        • McFarland K.
        • Kalivas P.W.
        The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior.
        J Neurosci. 2001; 21: 8655-8663
        • Prisciandaro J.J.
        • McRae-Clark A.L.
        • Myrick H.
        • Henderson S.
        • Brady K.T.
        Brain activation to cocaine cues and motivation/treatment status [published online ahead of print March 28].
        Addict Biol. 2012; (doi:10.1111/j.1369-1600.2012.00446)
        • Popik P.
        • Wrobel M.
        • Rygla R.
        • Bisaga A.
        • Bespakov A.Y.
        Effect of memantine, an NMDA receptor antagonist, on place preference conditioned with drug and nondrug reinforces in mice.
        Behav Pharmacol. 2003; 14: 237-244
        • Myers K.M.
        • Carlezon Jr, W.A.
        Extinction of drug- and withdrawal paired cues in animal models: Relevance to the treatment of addiction.
        Neurosci Biobehav Rev. 2010; 35: 118-126
        • Bespalov A.Y.
        • Zvartau E.E.
        • Balster R.L.
        • Beardsely P.M.
        Effects of N-methyl-D-aspartate receptor antagonists on reinstatement of cocaine-seeking behavior by priming injections of cocaine or exposures to cocaine-associated cues in rats.
        Behav Pharmacol. 2000; 11: 37-44
        • Collins E.D.
        • Ward A.S.
        • McDowell D.M.
        • Foltin R.W.
        • Fischman M.W.
        The effects of memantine on the subjective, reinforcing, and cardiovascular effects of cocaine in human.
        Behav Pharmacol. 1998; 9: 587-598
        • Bisaga A.
        • Aharonovich E.
        • Cheng W.Y.
        • Levin F.R.
        • Mariani J.J.
        • Raby W.N.
        • Nunes E.V.
        A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period.
        Drug Alcohol Depend. 2010; 111: 97-104
        • Price K.L.
        • McRae-Clark A.L.
        • Saladin M.E.
        D-cycloserine and cocaine cue reactivity: Preliminary findings.
        J Drug Alcohol Abuse. 2009; 35: 434-438
        • Skolnick P.
        • Popik P.
        • Trullas P.
        Glutamate-based antidepressants: 20 years on.
        Trends Pharmacological Sci. 2009; 30: 563-569
        • Almeida R.F.
        • Thomazi A.P.
        • Godinho G.F.
        • Saute J.A.
        • Wofchuk S.T.
        • Souza D.O.
        • et al.
        Effects of depressive-like behavior of rats on brain glutamate uptake.
        Neurochem Res. 2010; 35: 1164-1171
        • Mathew S.J.
        • Shah A.
        • Lapidus K.
        • Clark C.
        • Jarun N.
        • Ostermeyer B.
        • et al.
        Ketamine for treatment-resistant unipolar depression: Current evidence.
        CNS Drugs. 2012; 26: 189-204
        • Maeng S.
        • Zarate Jr, C.A.
        • Du J.
        • Schloesser R.J.
        • McCammon J.
        • Chen G.
        • et al.
        Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid receptors.
        Biol Psychiatry. 2008; 63: 349-352
        • Li N.
        • Lee B.
        • Liu R.J.
        • Banasr M.
        • Dwyer J.M.
        • Iwata M.
        • et al.
        mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
        Science. 2010; 20: 959-964
        • Goldstein R.Z.
        • Volkow N.D.
        Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex.
        Am J Psychiatry. 2002; 159: 1642-1652
        • Kosten T.A.
        • SCanley B.E.
        • Tucker K.A.
        • Oliveto A.
        • Prince C.
        • Sinha R.
        • et al.
        Cue-induced brain activity changes and relapse in cocaine dependent patients.
        Neuropsychopharmacology. 2006; 31: 644-650
        • Goldstein R.Z.
        • Tomasi D.
        • Rajaram S.
        • Cottone L.A.
        • Zhang L.
        • Maloney T.
        • et al.
        Role of the anterior cingulate and medial orbitofrontal cortex in processing drug cues in cocaine addiction.
        Neuroscience. 2007; 144: 1153-1159
        • Miller W.R.
        • Rollnick S.
        Motivational Interviewing, Third Edition: Preparing People for Change.
        Guilford Publications, New York2012
        • Salvadore G.
        • Cornwell B.R.
        • Colon-Rosario V.
        • Coppola R.
        • Grillon C.
        • Zarate C.A.
        • et al.
        Increased anterior cingulate cortical activity in response to fearful faces: A neurophysiological biomarker that predicts rapid antidepressant response to ketamine.
        Biol Psychiatry. 2009; 65: 289-295
        • Moghaddam B.
        • Adams B.
        • Verma A.
        • Daly D.
        Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.
        J Neurosci. 1997; 17: 2921-2927
        • Price R.B.
        • Nock M.K.
        • Charney D.S.
        • Mathew S.J.
        Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
        Biol Psychiatry. 2009; 66: 522-526
        • Perry E.B.
        • Cramer J.A.
        • Cho H.S.
        • Petrakis I.L.
        • Karper L.P.
        • Genovese A.
        • et al.
        Psychiatric safety of ketamine in psychopharmacology research.
        Psychopharmacology. 2007; 192: 253-260
        • Sklar G.S.
        • Zukin S.R.
        • Reilly T.A.
        Adverse reactions to ketamine anesthesia: abolition by psychological technique.
        Anesthesia. 1981; 36: 183-187
        • DiClemente C.C.
        • Hughes S.O.
        Stages of change profiles in alcoholism treatment.
        J Subst Abuse. 1990; 2: 217-235
        • Siegal H.A.
        • Li L.
        • Rapp R.C.
        • Saha P.
        Measuring readiness for change among crack cocaine users: a descriptive analysis.
        Subst Use Misuse. 2001; 36: 687-700
      2. SPSS (2011): SPSS. Cary, NC: SPSS.

        • Kalapatapu R.K.
        • Bedi G.
        • Haney M.
        • Evans S.M.
        • Rubin E.
        • Foltin R.W.
        Substance use after participation in laboratory studies involving smoked cocaine self-administration.
        Drug Alcohol Depend. 2012; 120: 162-167
        • Wilson S.J.
        • Sayette M.A.
        • Fiez J.A.
        Prefrontal responses to drug cues: A neurocognitive analysis.
        Nat Neurosci. 2004; 7: 211-214
        • Myers K.M.
        • Carlezon Jr, W.A.
        D-cycloserine effects on extinction of conditioned responses to drug-related cues.
        Biol Psychiatry. 2012; 71: 947-955
        • Hijazi Y.
        • Bodonian C.
        • Bolon M.
        • Salord F.
        • Boulieu R.
        Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury.
        Br J Anaesth. 2003; 90: 155-160
        • Markou A.
        • Kosten T.R.
        • Koob G.F.
        Neurobiological similarities in depression and drug dependence: A self-medication hypothesis.
        Neuropsychopharmacology. 1998; 18: 135-174
        • Vollenweider F.X.
        • Kometer M.
        The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders.
        Nat Rev Neurosci. 2010; 11: 642-651
        • Johnson M.
        • Richards W.
        • Griffiths R.
        Human hallucinogen research: Guidelines for safety.
        J Psychopharmacol. 2008; 22: 603-620
        • Miller W.R.
        • C’de Baca J.
        Quantum Change: When Epiphanies and Sudden Insights Transform Ordinary Lives.
        Guilford, New York2001
        • Griffiths R.R.
        • Richards W.A.
        • McCann U.
        • Jesse R.
        Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
        Psychopharmacology (Berl). 2006; 187 (discussion 284–292): 268-283
        • Krupitsky E.M.
        • Grinenko A.Y.
        Ketamine psychedelic therapy (KPT): A review of the results of ten years of research.
        J Psychoactive Drugs. 1997; 29: 165-183
        • Machado-Vieira R.
        • Manji H.K.
        • Zarate C.A.
        The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
        Neuroscientist. 2009; 15: 525-539
        • Preskhorn S.H.
        • Baker B.
        • Kolluri S.
        • Menniti F.S.
        • Krams M.
        • Landen J.W.
        An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101.606, in patients with treatment refractory major depressive disorder.
        J Clin Psychopharmacology. 2008; 28: 631-637